Floatz logo

Carboplatin

First-Line

Danish Oncological Lung Cancer GroupSmall moleculePhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

4 Active assets in the First-Line cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
Danish Oncological Lung Cancer Group
Phase 3B
ETOPOSIDE
Danish Oncological Lung Cancer Group
Phase 3B
Hycamtin
Danish Oncological Lung Cancer Group
Phase 3B
Capecitabine
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2CCC
Tislelizumab
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2CCC

View all 9 →

Same molecule, other indications

Carboplatin is also rated in:

lung large cell carcinomaDormant
A
Indicative ·
80 / 100
View asset →
non-small cell squamous lung carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →